Valneva Reports Positive Phase II Results for its Clostridium Difficile Vaccine Candidate

1 December 2015

valneva-200x200Valneva SE, a leading pure-play vaccine company, announced today, positive Phase II results for its prophylactic vaccine candidate against Clostridium difficile (C.difficile) infection (CDI). The key objectives of this Phase II trial have been met, the vaccine candidate generated strong immune responses against C. difficile toxins A and B, and the safety and tolerability profile was good.


Read the full press release